Safety of Antithymocyte Globulin Use in Kidney Graft Recipients During the COVID-19 Pandemic


Posted: 2021-10-26 19:00:00
BACKGROUND There are many safety concerns regarding the use of antithymocyte globulin (ATG) in kidney transplant recipients (KTRs) during the ongoing COVID-19 pandemic. Hereby, we present our recent experience with ATG administration both as induction therapy and as an anti-rejection treatment. MATERIAL AND METHODS We retrospectively analyzed all patients transplanted during the first 12 months of the COVID-19 pandemic who were treated with thymoglobulin. The ATG dosing, lymphocyte number and percentage in blood smear, adverse effects (thrombocytopenia and infectious complications), and kidney graft function up to 12 months and patients' outcomes were analyzed and compared to KTRs who received basiliximab induction. RESULTS During pandemic, a total of 31 patients were treated with ATG and 59 received basiliximab. The median cumulative ATG doses were 275 (175-325) mg in the induction subgroup and 263 (200-275) mg in the anti-rejection treatment subgroup. Mild thrombocytopenia was noted in 7 (22.6%) and 13 (29.5%) patients, respectively. There were more infectious complications among patients treated with ATG as compared with the basiliximab subgroup (32.3 vs 10.2%, P<0.01), but there were similar incidence rates of thrombocytopenia. Kidney graft function up to 12 months after transplant was comparable (1.1 [1.0-1.9] vs 1.1 [1.0-1.4] mg/dl, respectively). CONCLUSIONS 1. ATG use in the induction protocol or as the anti-rejection treatment during the COVID-19 pandemic appears to be safe and the risk of adverse events is acceptable. 2. During the COVID-19 pandemic the necessary use of ATG should not be postponed, especially in KTRs with increased immunologic risk.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
7月 22, 2020 バイオアソシエイツ

新型コロナウイルスがin vitroで心臓細胞に感染することが最近の研究で判明

米国のシーダーズ・サイナイ病院による新しい研究で、 COVID-19 を引き起こすSARS-CoV-2(新型コロナウイルス)が心臓細胞に感染する可能性があり、COVID-19患者の心臓細胞が直接感染する可能性があることが示された。 2020年6月25日にCell Reports Medicineのオンラインで公開されたこの発見は、iPS細胞技術によって生産された心筋細胞を使用して行われた。この論文は、「ヒトiPSC由来の心筋細胞はSARS-CoV-2感染の影響を受けやすい(Human iPSC-Derived…

ゲスト 818人 と メンバー 4人 がオンラインです